ACER Acer Therapeutics Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 18 March 2020 Acer Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

   OND denies Acer's appeal but describes possible paths forward for EDSIVO™ ACER-001 bioequivalence trial complete; New Drug Application submission anticipated early 2021 Targeting osanetant Phase 1/2 trial initiation

2. 18 March 2020 Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDA's Office of New Drugs

   NEWTON, Mass., March 18, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and

3. 24 February 2020 Acer Therapeutics Announces ACER-001 for Urea Cycle Disorders Trial Shows Bioequivalence to BUPHENYL®

   NEWTON, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and

4. 16 December 2019 Acer Therapeutics Announces Full Enrollment of Part B in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders

   Part A Successfully Completed and Optimal Formulation of ACER-001 Identified  Results of Part B Expected in Q1 2020 with a Planned NDA Submission in Q1 2021 NEWTON, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Acer

5. 13 November 2019 Acer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

   NEWTON, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and

6. 28 October 2019 Acer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders

   NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and

7. 30 August 2019 Shareholder Alert: Robbins Arroyo LLP Reminds Investors Acer Therapeutics Inc. (ACER) Sued for Misleading Shareholders

   Shareholder rights law firm Robbins Arroyo LLP reminds investors that a purchaser of Acer Therapeutics Inc. (NASDAQ:ACER) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934

8. 29 August 2019 ACER IMMINENT DEADLINE: Rosen, A Top Ranked Law Firm, Announces Filing of Securities Class Action Lawsuit Against Acer Therapeutics Inc.; Important August 30th Deadline - ACER

   NEW YORK, Aug. 29, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acer Therapeutics Inc. (NASDAQ:ACER)

9. 28 August 2019 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Acer Therapeutics (NASDAQ: ACER) and Encourages Acer Investors to Contact the Firm

   Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased Acer Therapeutics,

10. 28 August 2019 2-DAY ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Acer Therapeutics, Inc.

    The law firm of Kessler Topaz Meltzer & Check, LLP reminds Acer Therapeutics, Inc. (NASDAQ:ACER) ("Acer") investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or

11. 27 August 2019 FINAL DEADLINE - Acer Therapeutics Inc. (ACER) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: August 30, 2019

    NEW YORK, Aug. 27, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Acer Therapeutics Inc. ("Acer" or the

12. 27 August 2019 Acer Therapeutics to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    NEWTON, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and

13. 26 August 2019 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fred's, Acer Therapeutics, Diebold Nixdorf, and Intelligent Systems and Encourages Investors to Contact the Firm

    NEW YORK, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Fred's, Inc. (NASDAQ:FRED), Acer Therapeutics,

14. 21 August 2019 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sunlands Technology Group, Fred's, Acer Therapeutics, and Ideanomics and Encourages Investors to Contact the Firm

    NEW YORK, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sunlands Technology Group (NYSE:STG), Fred's,